Research & Development

R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia

R1 Therapeutics has raised $77.5m in an oversubscribed Series A funding to advance AP306 for hyperphosphatemia in chronic kidney disease (CKD) patients.

FDA issues CRL to Aldeyra’s reproxalap drug application

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Aldeyra Therapeutics for its new drug application (NDA) of reproxalap to treat dry eye disease.

Sentynl and PRG partner for Progerinin licence

Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational molecule intended to treat Hutchinson-Gilford Progeria Syndrome (HGPS).

Biophytis and LynxKite expand alliance to boost AI-driven drug discovery

Biophytis has expanded its existing partnership with LynxKite Technologies to accelerate AI-driven longevity drug discovery, beginning with the MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy (MASSIVE) project.

PRISM BioLab partners with Receptor.AI for molecule discovery

PRISM BioLab has formed a collaboration with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally available small molecules.

PsiQuantum and National Cancer Center Japan partner on quantum computing

PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing within drug discovery and oncology.

Curatis and Neupharma sign development agreement for corticorelin in Japan

Switzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema in Japan.

FDA approves GSK’s Wellcovorin for cerebral folate deficiency

The US Food and Drug Administration (FDA) has granted its approval for the expanded use of GSK’s Wellcovorin (leucovorin calcium) tablets to treat cerebral folate deficiency (CFD) in patients with a confirmed variant in the folate receptor one (FOLR1) gene.

NewcelX and Eledon partner for NCEL-101 programme

NewcelX has signed a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL-101 programme for type 1 diabetes (T1D).